sábado, 8 de junio de 2024

'Outstanding' Results for Osimertinib in Unresectable Stage III EGFR+ NSCLC M. Alexander Otto, PA, MMS June 04, 2024

https://www.medscape.com/viewarticle/outstanding-results-osimertinib-unresectable-stage-iii-egfr-2024a1000ag4

No hay comentarios:

Publicar un comentario